Angela Pham, M.D.
Assistant Professor
Department:
MD-GASTROENTEROLOGY
Business Phone:
(352) 273-9400
Business Email:
angela.pham@medicine.ufl.edu
About Angela Pham
Growing up, I was fascinated by the biology surrounding me and the intricacy of the human body. Once I realized I could meld science and human interaction through the art of medicine, it was a straight shot from there to medical school. As I tell my patients, my passion for gastroenterology lies in its important role in my patients’ lives. The GI tract is the first frontier through which outsiders have a chance to invade the body through the gut mucosa. Therefore, choosing a GI specialist is like finding a confidant that you will trust for life. Now, as an assistant professor in the University of Florida Division of Gastroenterology, Hepatology & Nutrition, I strive to improve the ways we monitor the progression of inflammatory bowel disease (IBD) and to explore nutritional treatments for IBD. I treat my patients for various gastrointestinal conditions, including Crohn’s disease, ulcerative colitis, IBD, celiac disease, short bowel syndrome and intestinal fistulas.
My training began in East Lansing, Michigan, where I received my medical degree from Michigan State University College of Human Medicine. Subsequently, I completed my internal medicine and pediatric residency at Grand Rapids Medical Education Partners with MSU in Grand Rapids. Following my residency, I relocated to Gainesville, where I completed my gastroenterology fellowship at UF.
I am board certified by the American Board of Internal Medicine in medicine and by the American Board of Pediatrics in general pediatrics. Currently, I am the principle investigator for Project ECHO IBD, which aims to create a virtual learning community through video-teleconferencing by combining didactic with individualized clinical case review. I am thrilled to be working on this program because it has the potential to disseminate IBD knowledge to expedite patient care and treatment.
I am also a member of the American College of Physicians, American Academy of Pediatrics and American College of Gastroenterology. Outside of practice, I enjoy many things: cooking with new recipes, kayaking and going to bookstores to find my next-favorite fiction.
Teaching Profile
Courses Taught
2024
BMS6634 GI and Hepatology
Board Certifications
-
Internal MedicineAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Gastroenterology
Areas of Interest
- Crohn disease
- Inflammatory Bowel Disease
- Ulcerative colitis
Publications
Academic Articles
2024
Micronutrient deficiencies in inflammatory bowel disease: an incidence analysis.
European journal of gastroenterology & hepatology.
36(10):1186-1192
[DOI] 10.1097/MEG.0000000000002821.
[PMID] 39012640.
2024
Recurrence of Drug-Induced Lupus Secondary to Vedolizumab Use in a Patient With Crohn’s Disease.
ACG case reports journal.
11(1)
[DOI] 10.14309/crj.0000000000001270.
[PMID] 38274296.
2023
Healthcare Utilization Patterns and Excessive Steroid Use in Late Adolescence Age and Young Adults With Crohn’s Disease and Ulcerative Colitis.
Gastro hep advances.
2(7):928-934
[DOI] 10.1016/j.gastha.2023.06.009.
[PMID] 39130756.
2023
Perforation of the Transverse Colon After Migration of a Ventriculoperitoneal Shunt.
ACG case reports journal.
10(9)
[DOI] 10.14309/crj.0000000000001134.
[PMID] 37663235.
2023
Wernicke’s Encephalopathy in Type 2 Achalasia: Case Report and Literature Review.
Journal of investigative medicine high impact case reports.
11
[DOI] 10.1177/23247096231190628.
[PMID] 37539958.
2022
Carnitine Deficiency in an Adult With Short Bowel Syndrome After Surgical Resection.
ACG case reports journal.
9(6)
[DOI] 10.14309/crj.0000000000000799.
[PMID] 35765679.
2022
Concurrent zinc and vitamin B6 deficiencies in acutely exacerbated inflammatory bowel disease: Case reports.
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.
37(1):203-208
[DOI] 10.1002/ncp.10665.
[PMID] 33930197.
2022
Failure to thrive: A severe manifestation of interleukin 10 receptor A mutation in adult inflammatory bowel disease.
JPEN. Journal of parenteral and enteral nutrition.
46(1):238-242
[DOI] 10.1002/jpen.2254.
[PMID] 34423458.
2020
College Students with Inflammatory Bowel Disease: A Qualitative Study of Challenges Associated with College Transition and Self-Care.
Health equity.
4(1):190-197
[DOI] 10.1089/heq.2019.0053.
[PMID] 32440616.
2018
Chronic pancreatitis: review and update of etiology, risk factors, and management.
F1000Research.
7
[DOI] 10.12688/f1000research.12852.1.
[PMID] 29946424.
2018
Effective communication of cross-sectional imaging findings in Crohn’s disease: comparing conventional EMR reporting to a published scoring system.
Abdominal radiology (New York).
43(7):1798-1806
[DOI] 10.1007/s00261-017-1368-0.
[PMID] 29075825.
2017
Hematochezia: An Uncommon Presentation of Colonic Tuberculosis.
Case reports in gastrointestinal medicine.
2017
[DOI] 10.1155/2017/7831907.
[PMID] 28473931.
2013
Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis.
Journal of pediatric gastroenterology and nutrition.
56(6):597-601
[DOI] 10.1097/MPG.0b013e318292fa0d.
[PMID] 23542823.
Grants
Jul 2024
ACTIVE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to
Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis
Role: Principal Investigator
Funding: MERCK SHARP & DOHME
Jul 2024
ACTIVE
A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Role: Principal Investigator
Funding: ABBVIE
May 2024
ACTIVE
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects with Moderately to Severely Active Crohn's Disease
Role: Principal Investigator
Funding: ABBVIE
Mar 2024
ACTIVE
A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis
Role: Principal Investigator
Funding: GILEAD SCIENCES
Feb 2024
– Feb 2024
Practical Guidelines on Endoscopic Treatment of Crohn's Disease Strictures
Role: Principal Investigator
Funding: JANSSEN SCIENTIFIC AFFAIRS
Dec 2023
ACTIVE
CorEvitas Inflammatory Bowel Disease (IBD) Drug Safety and Effectiveness Registry
Role: Principal Investigator
Funding: COREVITAS
Nov 2023
ACTIVE
Project RISC: Resolving Inequities in Shared Decision-Making in Crohn's and Colitis
Role: Principal Investigator
Funding: PFIZER INC
Feb 2023
– Oct 2023
A Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Vurolenatide in Adult Patients with Short Bowel Syndrome (VIBRANT 2)
Role: Principal Investigator
Funding: 9 METERS BIOPHARMA
Sep 2022
– Jul 2024
A 54-Week, Multicenter, Randomized, Double-blind, Placebocontrolled,
Parallel-group Phase 2 Study to Assess the Efficacy
and Safety of Brazikumab in Participants with Moderately to
Severely Active Ulcerative Colitis (Expedition Lead-in)
Role: Principal Investigator
Funding: ASTRAZENECA PHARM
Jun 2022
– Aug 2023
A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
May 2022
– Oct 2023
A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohns Disease
Role: Principal Investigator
Funding: ASTRAZENECA PHARM
Feb 2022
– Nov 2023
Teduglutide for Treatment of Short Bowel Syndrome in Real World Settings:
Center-based Chart Review in the US
Role: Principal Investigator
Funding: ANALYSIS GROUP
via TAKEDA PHARMACEUTICAL COMPANY LIMITED
Aug 2021
– Sep 2023
A Phase 2, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study of the Efficacy, Safety, and Tolerability of Vurolenatide (NM-002) in Adult Patients with Short Bowel Syndrome
Role: Principal Investigator
Funding: 9 METERS BIOPHARMA
Apr 2021
– Jun 2024
College-aged patients with Inflammatory Bowel Disease (IBD); addressing unique needs and improving disease outcomes.
Role: Co-Investigator
Funding: ARENA PHARMACEUTICALS
Dec 2020
– Jun 2023
Project ECHO IBD
Role: Principal Investigator
Funding: PFIZER INC
Dec 2019
– Jul 2022
A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Aug 2019
– Aug 2024
A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY OF ORAL OZANIMOD FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Role: Principal Investigator
Funding: CELGENE CORP
Aug 2019
– Aug 2024
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Role: Principal Investigator
Funding: CELGENE CORP
Aug 2019
– Aug 2024
INDUCTION STUDY #1 – A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMODAS AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Role: Principal Investigator
Funding: CELGENE CORP
Jan 2018
– Dec 2024
A Prospective, Multi-center Registry for Patients with Short Bowel Syndrome
Role: Principal Investigator
Funding: SHIRE PHARMACEUTICAL DEV
Nov 2017
ACTIVE
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis
Role: Principal Investigator
Funding: GILEAD SCIENCES
Mar 2017
– Dec 2024
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT-494 in Subjects with Crohn's Disease
Role: Principal Investigator
Funding: ABBVIE
Mar 2017
– Apr 2023
An Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severely Active Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Protocol GA29144
Role: Principal Investigator
Funding: IQVIA Holdings
via GENENTECH INC
Jan 2017
– Feb 2024
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES
via GILEAD SCIENCES
Jan 2017
– Aug 2022
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Role: Principal Investigator
Funding: IQVIA Holdings
via GENENTECH INC
Jan 2017
– Jan 2024
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES
via GILEAD SCIENCES
Education
Fellowship – Gastroenterology
2015-2018
·
University of Florida
Residency – Internal Medicine
2011-2015
·
Grand Rapids Medical Education Partners/Michigan State University
Medical School
2011
·
Michigan State University College of Human Medicine
Contact Details
Phones:
- Business:
- (352) 273-9400
Emails:
- Business:
- angela.pham@medicine.ufl.edu
Addresses:
- Business Mailing:
-
PO BOX 1002214
GAINESVILLE FL 326100001 - Business Street:
-
PO BOX 1002214
GAINESVILLE FL 32611